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Products 
Rationale: Why focus on genetic testing? 
Over 1000 genetic tests are available for clinical use, most for diagnosis of
rare single-gene disorders. 
A growing number of tests have potential for broad public health impact. 
These include predictive tests for determining risk of common diseases and 
pharmacogenomic tests to help physicians choose the right drug and dosage 
for individual patients. 
Health care providers, consumers, and policy makers need evidence-based information to 
help determine which genetic tests are safe and effective, and provide guidance on their 
appropriate use. 
Working Group Recommendation Statements 
First recommendation statement published December 2007. 
Recommendations from the EGAPP Working Group: testing for 
cytochrome P450 polymorphisms in adults with nonpsychotic 
depression treated with selective serotonin reuptake inhibitors.
Genetics in Medicine 2007:9(12):819-825. 
Working Group recommendation statements are intended to provide guidance on the 
appropriate use of genetic tests in specific clinical scenarios, and highlight critical 
knowledge gaps. 
Conclusions are based on EGAPP-commissioned evidence reports and on subsequent 
analysis and deliberations by the Working Group on the strength of evidence and 
potential clinical and social impact of using the tests in practice.EGAPP: Evaluation of Genomic Applications in Practice and 
Prevention 
CDC established the EGAPP initiative to develop and test a systematic, evidence-based 
process for evaluating genetic tests and other applications of genomic technology in 
transition from research to clinical practice. 
The focus of EGAPP activities is an independent, multidisciplinary Working Group, 
established in 2005. The Working Group develops recommendations for selected genetic 
tests. 
Stakeholders provide input and feedback on EGAPP processes, products, and impact. 
Identify, prioritize, and select 
topics 
Develop and optimize methods for 
collecting and grading evidence on 
genomic tests 
Consider specific family or societal 
outcomes in addition to clinical 
outcomes 
Assess usefulness of modeling 
Submit recommendations for peer 
review 
Provide recommendations with linkage to the evidence 
Topics 
EGAPP reviews focus on 
Tests recognized as having wide population application 
e.g., higher disorder prevalence or frequency of test use 
Tests with the potential to impact clinical and public health practice 
e.g., tests used in a specific clinical scenario to guide intervention and tests for risk 
prediction or population screening 
EGAPP-Commissioned Evidence Reports 
Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes. Johns 
Hopkins University AHRQ Evidence-based Practice Center | January 2008 
Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their 
Implications. Tufts New England Medical Center Evidence Based Practice Center | 
May 2007 
Testing for Cytochrome P450 Polymorphisms (CYP450) in Adults with 
Non-Psychotic Depression Prior to Treatment with Selective Serotonin 
Reuptake Inhibitors (SSRIs). Duke University AHRQ Evidence-based Practice Center | 
January 2007 
Genomic Tests for Ovarian Cancer Detection and Management. Duke University
AHRQ Evidence-based Practice Center | October 2006 
Working Group Website 
www.egappreviews.org 
EGAPP Process Publications 
Three publications are in preparation that describe the EGAPP initiative and Working Group 
An overview of EGAPP processes and their rationale 
A description of Working Group review methodology 
A discussion of clinical and social contextual outcomes of genetic testing considered by 
the Working Group 
Translational Materials for Providers and Consumers 
Materials based on EGAPP Working Group informational messages will be developed with 
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Clinical ScenarioDisorder/Effect Test to be
Assessed 
Target Population Intended Use 
Breast Cancer Gene expression
profile 
Women diagnosed with breast cancer Treatment and recurrence risk
Cardiovascular Disease Multigene panels General population Risk prediction or nutritional/lifestyle
management 
Colorectal Cancer (CRC) UGT1A1 Individuals diagnosed with CRC Treatment with irinotecan





Individuals diagnosed with CRC and their family 
members 
Management of individuals and early
detection/prevention for family members 
Ovarian Cancer Genomic Tests 1) General population of women and;
2) women at increased risk for ovarian cancer 





1) Personal and/or family history of venous
thromboembolism, or
2) family history of Factor V Leiden mutation 
Diagnosis and management for
individuals; prevention for family
members 
Stakeholder Involvement 
Genetic testing stakeholders include health care providers and payers, policy makers, 
public health professionals, educators, and consumers. These and other stakeholders are 
engaged in numerous ways in EGAPP processes, products, and evaluation. 
EGAPP Stakeholders Group (ESG). The 35-member ESG was established in October 
2007 to provide input on products and on the best approaches for disseminating and 
translating key messages from EGAPP evidence reviews. The first ESG meeting was held 
in January 2008. 
Surveys. EGAPP will survey stakeholders to obtain feedback on the processes, products, 
and impact of the early phase of the EGAPP initiative. 
Reviewers. Stakeholders may be recruited by the Working Group as expert or peer 
reviewers for evidence reports or recommendation statements. 
Meetings.  Meetings of the ESG and EGAPP Working Group provide opportunities for 
stakeholder comments and questions. 
Topic suggestions. Stakeholders are welcome to suggest topics and comment on 
EGAPP processes or products via the EGAPP Working Group website 
(www.egappreviews.org). 
Coming Soon 
Opinions and recommendations of the EGAPP Working Group, and www.egappreviews.org website 
content, are not designed to be advice to the Federal government and should not be construed as 
official positions of the CDC or the U.S. Department of Health and Human Services. 
Overview 
Coming Soon 
Topics Currently Under Review or Completed 
